Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Q&a

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Apr 21, 2023 2:24am

94 Views

Post# 35406619

RE:RE:RE:RE:RE:RE:Q&a

"The Board has begun a strategic review of every facet of the company including management, organizational structure, project pipeline, financial position and the exchanges on which the Sirona shares are listed."

"Organizational changes and management expansion will occur in both, our headquarters in

Vancouver, Canada and our research facility in Rouen, France."

"External resources will be engaged to assist and there will be updates communicated throughout

the remainder of 2022."

Did I miss this along the way? And we're now near the end of April 2023.

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?